Earnings call transcript: Physitrack’s Q1 2026 marks profitability milestone

Physitrack posted its first profit on continuing operations in Q1 2026, with net income of EUR 58,000 versus a EUR 376,000 loss a year ago, while revenue rose 3% to EUR 3.2 million (6% constant currency). Adjusted EBITDA reached EUR 1.1 million and free cash flow stayed positive at EUR 0.1 million, though reported growth was dampened by FX headwinds and shares fell 4.22% after the update. Management highlighted RTM as the key growth catalyst, with launch expected in Q2 2026 and a potential 3-10x uplift in monthly license revenue per customer.

Analysis

The important signal here is not the first profitable quarter; it’s that the business is crossing from survival mode into a self-funding product cycle just as it launches a monetization layer that can re-rate customer economics. That matters because RTM should expand deal size, shorten sales cycles, and reduce churn by tying the product to reimbursement rather than budget discretion. In other words, the next leg is less about top-line growth optics and more about conversion of a small installed base into a materially higher ARPU regime.

The market is likely discounting execution risk around timing and adoption curve. The near-term setup is asymmetric because the Q2 catalyst is binary: if pilot conversions show real usage and pricing lift, investors will start capitalizing RTM at a higher multiple; if not, the story stays stuck in “nice software, small scale.” The second-order effect is that any success in North America also increases the value of the OTCQX path and potential buyback framework, both of which can tighten the shareholder base and improve tape behavior.

The contrarian view is that the move is underappreciated because the market is still treating this as a low-quality microcap with FX noise and one-off adjustments, while the underlying business is becoming more cash generative and structurally less cyclical. The real risk is not near-term profitability; it’s whether the company can convert a reimbursement narrative into repeatable enterprise adoption before the operating leverage plateaus. If RTM uptake is slower than implied, the stock likely de-rates back to a cash-box multiple; if it lands even modestly, the multiple can expand quickly because incremental revenue should carry very high flow-through.

Key Decisions for Investors

• Long NEXA on a 1-3 month horizon into RTM launch data; target a 20-30% rerating if the first pilots show measurable ARR uplift, with downside limited if cash generation remains positive.
• Buy NEXA call spreads 2-4 months out to express asymmetric upside on RTM adoption while capping premium risk; best entry is on any post-announcement weakness or flat tape after launch.
• Pair trade: long NEXA / short a lower-margin healthcare software microcap with no reimbursement-linked catalyst over the next quarter; the relative trade favors companies where monetization is tied to payer economics rather than discretionary spend.
• If Q2 shows no conversion from the RTM pipeline, reduce or hedge the long quickly; the stock likely reverts toward a profitability-only story and loses narrative premium.
• Monitor any OTCQX/buyback announcement as a secondary catalyst; if both are confirmed, add on confirmation because liquidity and capital-return optics could compress the discount to intrinsic value.